Nurix Therapeutics (NRIX) Institutional Ownership

Of the 186 institutional investors that purchased Nurix Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: FMR LLC ($10.56M), General Atlantic L.P. ($4.90M), Vestal Point Capital LP ($4.27M), Perceptive Advisors LLC ($3.09M), Morgan Stanley ($2.62M), Rubric Capital Management LP ($2.47M), and Braidwell LP ($2.18M).

Institutional investors have bought a total of 40,018,472 shares in the last 24 months. This purchase volume represents approximately $679.11M in transactions.

Of the 54 institutional investors that sold Nurix Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: T. Rowe Price Investment Management Inc. ($2.07M), Commodore Capital LP ($1.70M), Millennium Management LLC ($1.34M), UBS Group AG ($1.23M), Pictet Asset Management Holding SA ($741.46K), Redmile Group LLC ($680.14K), and Sumitomo Mitsui Trust Group Inc. ($376.33K).

Institutional investors have sold a total of 10,588,767 shares in the last 24 months. This volume of shares sold represents approximately $164.53M in transactions.